ACE2 and COVID-19: Since only AT1R is blocked, using an ARB (angiotensin receptor blockers) for the therapy of COVID-19 patients may have favorable outcomes because any formed Ang II may have anti-inflammatory effects through its interaction with AT2R or through conversion by residual ACE2 to Ang (1–7) acting through AT2R, MasR, and Mas-related G protein-coupled receptor D) [20].